Table 2.
Median OS (months) | HR (95% CI) | |
---|---|---|
First line | ||
Lenvatinib vs. Sorafenib | 13.6 vs. 12.3 | 0.92 (0.79 – 1.06) |
Second line | ||
Regorafenib vs. Placebo | 10.6 vs. 7.8 | 0.63 (0.50 – 0.79) |
*Nivolumab (Sor experienced: ESC/EXP) | 15.0/15.6 | NA |
Ramucirumab vs. Placebo | 8.5 vs. 7.3 | 0.710 (0.531–0.949) |
Cabozantinib vs. Placebo | 10.2 vs. 8.0 | 0.76 (0.63 – 0.92) |
phase I/II trial